TRT and Cardiovascular Health: What the Evidence Says

One of the most common concerns men bring up before starting testosterone replacement therapy is heart health. For years, headlines suggested TRT might raise the risk of heart attacks and strokes. The research picture has shifted considerably since then, and what the evidence actually shows is worth understanding before you have a conversation with your own clinician.

This is not a simple topic, but it does not have to be a confusing one. Here is a plain-English overview of where the science stands, what the main risks and reassurances are, and what questions are worth asking.

Where the Concern Came From

The worry about TRT and heart disease started around 2010-2014, when a handful of observational studies and one clinical trial suggested a possible link between testosterone therapy and cardiovascular events. These findings got significant media coverage. As a result, the FDA added a warning label to testosterone products in 2015, noting the issue had not been fully resolved.

The problem with those early studies is that many had serious design flaws. Some included men who had already been diagnosed with heart conditions. Others compared apples to oranges – men on TRT versus men who had never needed it in the first place, which tells you little about the therapy itself.

What Larger, Newer Research Shows

The most significant update came from the TRAVERSE trial, a large randomized controlled study published in the New England Journal of Medicine in 2023. It specifically enrolled men with low testosterone who also had pre-existing cardiovascular risk factors or confirmed disease – the highest-risk group possible.

The key finding: testosterone therapy did not significantly increase the rate of major cardiovascular events (heart attack, stroke, or cardiovascular death) compared to placebo. This was meaningful because it tested TRT in the population where risk was presumed to be highest.

That said, the trial also found higher rates of atrial fibrillation, pulmonary embolism (blood clots in the lungs), and acute kidney injury in the testosterone group. So the picture is not entirely clean. These are findings your clinician should know about when assessing whether TRT is appropriate for you.

The Red Blood Cell Factor

One mechanism that links TRT to cardiovascular concern is its effect on red blood cell production. Testosterone stimulates the body to produce more red blood cells, which can thicken the blood and raise the risk of clotting. This is called erythrocytosis, and it is one of the main reasons regular bloodwork is required during TRT.

When hematocrit – the percentage of blood made up of red blood cells – climbs too high, a clinician may adjust the dose, switch delivery methods, or recommend therapeutic phlebotomy (donating blood). Monitoring this is a standard part of responsible TRT care.

Who Faces Higher Cardiovascular Risk on TRT

Risk is not the same for everyone. Certain factors make cardiovascular monitoring more important during TRT:

• Pre-existing heart disease or history of stroke
• History of blood clots or clotting disorders
• Atrial fibrillation
• Polycythemia (already elevated red blood cell count before starting)
• Smoking and obesity, which compound clotting risk

If any of these apply to you, that does not automatically rule out TRT – but it does make a thorough pre-treatment evaluation and ongoing monitoring more critical, not optional.

What This Means Practically

The bottom line from current evidence is that TRT does not appear to dramatically raise the risk of heart attack or stroke in men without pre-existing severe cardiovascular disease, when properly monitored. But it is not risk-free either, particularly around blood clotting and certain arrhythmias.

The right approach is a frank conversation with your own clinician about your personal cardiovascular history, current risk factors, and what monitoring schedule makes sense if you do start therapy. A short overview like this one is a useful starting point – for the full clinical picture on cardiovascular screening, bloodwork thresholds, and dosing decisions, the deeper guide on the USTRT sister site covers that ground in more detail.

Frequently Asked Questions

Does TRT cause heart attacks?

The largest randomized trial to date – the TRAVERSE trial, published in 2023 – found that TRT did not significantly increase the rate of major cardiovascular events like heart attacks or strokes compared to placebo, even in men with existing heart disease risk. However, some secondary risks like blood clots and atrial fibrillation were higher in the TRT group, so this is not the same as saying TRT is entirely risk-free for the heart.

Is TRT safe if I already have heart disease?

It depends on the specifics of your diagnosis and current health status – this is a direct question for your own cardiologist or prescribing clinician. The TRAVERSE trial did include men with cardiovascular disease and did not find a dramatic increase in major events, but individual risk factors matter significantly, and close monitoring is essential in this group.

Why does TRT affect blood clotting?

Testosterone stimulates the bone marrow to produce more red blood cells, which can raise hematocrit (blood thickness) to levels that increase clotting risk. This is why clinicians monitor hematocrit regularly during TRT and may adjust the dose or recommend donating blood if levels climb too high.

Does the delivery method affect cardiovascular risk?

There is some evidence that injectable forms of testosterone raise hematocrit more sharply than gels or patches, because injections can produce higher peak testosterone levels. Your clinician may factor this into which delivery method they recommend based on your cardiovascular profile.

What cardiovascular tests should be done before starting TRT?

At minimum, a baseline hematocrit and hemoglobin check, blood pressure review, and a discussion of personal and family cardiovascular history are standard before starting therapy. Men with known heart conditions or clotting history may need additional workup before a prescribing decision is made.